Literature DB >> 33314340

The effect of Lucilia sericata larval excretion/secretion (ES) products on cellular responses in wound healing.

U Gazi1, A Taylan-Ozkan1,2, K Y Mumcuoglu3.   

Abstract

Chronic wounds are still regarded as a serious public health concern, which are on the increase mainly due to the changes in life styles and aging of the human population. There are different types of chronic wounds, each of which requires slightly different treatment strategies. Nevertheless, wound bed preparation is included in treatment of all types of chronic wounds and involves tissue debridement, inflammation, and infection control, as well as moisture balance and epithelial edge advancement. Maggot therapy (MT) is a form of biological debridement which involves the application of live medical grade Lucilia sericata (Meigen, 1826) (Diptera: Calliphoridae) larvae. Whereas it was initially thought to act mainly through debridement, today MT is known to influence all four overlapping physiological phases of wound repair: homeostasis, inflammation, proliferation, and remodelling/maturing. During MT, medical-grade larvae are applied either freely or enclosed in tea-bag like devices (biobag) inside the wounds, which suggests that larva excretion/secretion (ES) products can facilitate the healing processes directly without the need of direct contact with the larvae. This review summarizes the relevant literature on ES-mediated effects on the cellular responses involved in wound healing.
© 2020 The Royal Entomological Society.

Entities:  

Keywords:  Chronic wound; Lucilia cuprina; Lucilia sericata; excretion; healing; maggot therapy; secretion

Year:  2020        PMID: 33314340     DOI: 10.1111/mve.12497

Source DB:  PubMed          Journal:  Med Vet Entomol        ISSN: 0269-283X            Impact factor:   2.739


  1 in total

1.  Lucillia Sericata larval therapy in the treatment of diabetic chronic wounds.

Authors:  Arash Jafari; Seyed Vahid Hosseini; Hossein Javaheri Hemmat; Hajar Khazraei
Journal:  J Diabetes Metab Disord       Date:  2022-01-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.